FIGURE 4.

Part B, multiple‐ascending dose, clinical characterisation of ESM‐HDAC391. (A, B) Quantification of HDAC189 levels in monocyte and non‐monocyte fractions per dose cohort. (C, D) Acetylation levels in gated monocyte, lymphocyte and granulocyte populations for each assessed timepoint and dose cohort. (E–H) Time course of inhibition of ex vivo LPS‐stimulated cytokine production (tumour necrosis factor [TNF]α in E, F and interleukin [IL]‐6 in G‐H) per dose cohort. Panels A, C, E, G represent Day 1 data; panels B, D, F, H represent Day 7 data. Data are shown as mean and standard error. For all panels, 20 mg (n = 3) and 40 mg (n = 7) data are included. For panels E‐H, n = 3 placebos (n = 1 from 20 mg and n = 2 from 40 mg cohort) were included